ヒト成長ホルモンの世界市場：用途別・投与経路別・流通チャネル別・地域別 - 市場分析、シェア、動向、規模、予測 (2020～2026年)
Human Growth Hormone Market, By Application, By Route of Administration, By Distribution Channel, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2020-2026
|ヒト成長ホルモンの世界市場：用途別・投与経路別・流通チャネル別・地域別 - 市場分析、シェア、動向、規模、予測 (2020～2026年)|
発行: AnalystView Market Insights
ページ情報: 英文 206 Pages
当レポートでは、世界のヒト成長ホルモン (hGh) 市場について分析し、市場の定義や基本構造、主な市場促進・抑制要因、業界の競争力・求心力、市場シェア構造、用途別・投与経路別・流通チャネル別・地域別の市場動向見通し (過去4年間・今後8年間分)、主要企業のプロファイルなどについて調査しております。
The human growth hormone market was valued at USD 4.53 billion by 2019, growing with 8.1% CAGR during the forecast period, 2020-2026.
Human growth hormone (hGh) also called somatotropin is a proteohormone produced by the pituitary gland that regulates reproduction, cell regeneration & repair, metabolism, and cell growth spurring the overall development of humans. For normal growth of the human body, the growth hormone levels should be optimum that can be regulated by factors such as lower glucose levels, exercise, sleep, and reduced stress levels. These hormones help in controlling body composition, body fluids, muscle & bone growth, recovery from injury, and sugar & fat metabolism. The human growth hormone also helps to boost muscle performance and strength.
The growing awareness related to the effectiveness of growth hormones and the growing prevalence of serious chronic diseases such as pituitary dysfunctions, kidney diseases are the major factors driving the growth of the global human growth hormone market. According to the Centers for Diseases Control & Prevention (CDC), around 6,000 adults in the U.S. are diagnosed with growth hormone deficiency each year. The incidence of growth human deficiency in adults has been estimated to affect 1 in 100,000 people every year, whereas in children it's 2 cases per 100,000 annually. Furthermore, the surge in compliance for growth hormone (GH) formulations and the rising demand for cost-effective GH therapies are other factors boosting the market growth. Conversely, the high costs related to the human growth hormone therapies and the adverse effects associated with these therapies are expected to hinder the market growth in the coming future. On the contrary, the presence of strong pipeline, investments by major market players, rising government initiatives, and extensive R&D activities are predicted to create lucrative growth opportunities in the overall market during the period of forecast.
Based on the application, the global market for human growth hormone is categorized into turner syndrome, growth hormone deficiency, idiopathic short stature, small for gestational age, and prader-willi syndrome. The growth hormone deficiency is further sub-categorized into pediatric growth hormone deficiency and adult growth hormone deficiency. Among these, the growth hormone (GH) deficiency segment accounted for the majority of market share in 2019 and is anticipated to play a dominant role during the forecast period. This dominance is majorly attributed to growing awareness amongst individuals regarding early diagnosis and treatment of growth hormone deficiency. In addition, the rise in the number of R&D activities and the introduction of novel drugs in the hGh market are other factors propelling the segmental market growth.
On the other hand, the turner syndrome segment is estimated to hold the second-largest share in the market during the period of forecast owing to the growing initiatives by various private and public organizations to spread awareness regarding the early diagnosis and treatment of turner syndrome.
Route of Administration Takeaway
Based on the route of administration, the overall hGh market is categorized into subcutaneous, oral, intramuscular, and intravenous. Of these, the subcutaneous segment subjugated the global hGh market in 2019 and is expected to maintain its dominance in the projected timeframe by 2026. This is mainly because the growth hormones when administered subcutaneously have more bioavailability than the other routes of administration. On the other hand, the oral route of administration segment is anticipated to witness lucrative growth during the forecast period owing to technological advancements and increasing R&D activities regarding the novel introduction of drugs.
Distribution Channel Takeaway
Based on the distribution channel, the worldwide market for human growth hormone is categorized into online pharmacy, retail pharmacy, hospital pharmacy, and specialty pharmacy. Among these, the hospital pharmacy segment held the largest market share in 2019 and is anticipated to witness progressive growth during the forecast period. This is mainly owing to increasing visits to hospitals coupled with growing awareness regarding growth hormone deficiency amongst individuals and its treatment. On the other hand, the online pharmacy segment is anticipated to grow at a significant rate in the projected timeframe owing to the high penetration of pharmacies mainly in developed regions of Europe and North America.
Regionally, the global industry is divided into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. The North America region registered for the majority of shares in the market in 2019 and is estimated to dominate the industry during the forecast period. This dominance is majorly attributed to favorable reimbursement scenario, increasing healthcare awareness, well-established healthcare infrastructure, and significant government initiatives. In addition, the presence of major market players in the region and increased access to novel drugs are other factors impelling the regional market growth. On the other hand, the Asia Pacific market for human growth hormone is estimated to value for the highest growth in the forecast period owing to the focus of major market players towards gaining a major market share in potential countries of this region.
The COVID-19 pandemic is anticipated to positively impact the global human growth hormone market owing to the heightened product innovations in this unprecedented situation. The key players of the market are increasingly investing in technological advancements and R&D activities to introduce novel drugs. This has helped the overall market to grow exponentially during the coronavirus chaos. Also, the market is expected to witness a tremendous growth post-COVID-19 pandemic estimated period.
KEY VENDOR TAKEAWAY
The leading players of the global human growth hormone market include Ipsen, Ferring B.V., Novartis AG, Genetech, Inc., Merck KGaA, Sandoz International GmbH, Eli Lily and Company, Pfizer, Inc., Novo Nordisk A/S, Teva Pharmaceutical Limited, and AnkeBio Limited. These players are implementing several strategies such as mergers, acquisitions, and partnerships to hold a strong position in the global industry.
For instance, in February 2018, Ispen and Arix Bioscience entered into a strategic agreement with an aim to develop innovatively and commercialize human growth hormone deficiency therapies.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year - 2015 to2018
Base Year - 2019
Estimated Year - 2020
Projected Year - 2026
Traders, Distributors, and Suppliers
Government and Regional Agencies
Scope of the Report
The scope of this report covers the market by its major segments, which include as follows:
HUMAN GROWTH HORMONE MARKET KEY PLAYERS
Sandoz International GmbH
Eli Lily and Company
Novo Nordisk A/S
Teva Pharmaceutical Limited
HUMAN GROWTH HORMONE MARKET, BY APPLICATION
Growth Hormone Deficiency
Pediatric Growth Hormone Deficiency
Adult Growth Hormone Deficiency
Idiopathic Short Stature
Small for Gestational Age
HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION
HUMAN GROWTH HORMONE MARKET, BY DISTRIBUTION CHANNEL
HUMAN GROWTH HORMONE MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA